跳至主要内容
临床试验/CTRI/2021/12/038578
CTRI/2021/12/038578已完成未知

A non-interventional, multicenter study to determine the prevalence of homologous recombination repair (HRR) gene mutations in patients with metastatic castration-resistant prostate cancer in India - PROSPECT

AstraZeneca Pharma India Ltd0 个研究点目标入组 211 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
211

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1.Male participants aged =18 = 80 years of age.
  • 2. Pathological mCRPC cases confirmed by laboratory (PSA and testosterone levels), X-rays (optional),(CT scan/ MRI scan / PET scan) .
  • 3. Availability of medical history (demographic information and history of cancer)
  • 4. Participants who are able to provide written informed consent form (ICF).

排除标准

  • 1. Diagnosis of any severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of the study results.
  • 2. Newly diagnosed mCRPC participants without tissue sample availability.

研究者

相似试验